Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AIDS Res Hum Retroviruses. 2019 Jun 27. doi: 10.1089/AID.2018.0270. [Epub ahead of print]

PMID:
31115244
2.

Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency.

Farmer JR, Foldvari Z, Ujhazi B, De Ravin SS, Chen K, Bleesing JJH, Schuetz C, Al-Herz W, Abraham RS, Joshi AY, Costa-Carvalho BT, Buchbinder D, Booth C, Reiff A, Ferguson PJ, Aghamohammadi A, Abolhassani H, Puck JM, Adeli M, Cancrini C, Palma P, Bertaina A, Locatelli F, Di Matteo G, Geha RS, Kanariou MG, Lycopoulou L, Tzanoudaki M, Sleasman JW, Parikh S, Pinero G, Fischer BM, Dbaibo G, Unal E, Patiroglu T, Karakukcu M, Al-Saad KK, Dilley MA, Pai SY, Dutmer CM, Gelfand EW, Geier CB, Eibl MM, Wolf HM, Henderson LA, Hazen MM, Bonfim C, Wolska-Kuśnierz B, Butte MJ, Hernandez JD, Nicholas SK, Stepensky P, Chandrakasan S, Miano M, Westermann-Clark E, Goda V, Kriván G, Holland SM, Fadugba O, Henrickson SE, Ozen A, Karakoc-Aydiner E, Baris S, Kiykim A, Bredius R, Hoeger B, Boztug K, Pashchenko O, Neven B, Moshous D, Villartay JP, Bousfiha AA, Hill HR, Notarangelo LD, Walter JE.

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1970-1985.e4. doi: 10.1016/j.jaip.2019.02.038. Epub 2019 Mar 12.

3.

Funding Pediatric Subspecialty Training: Are T32 Grants the Future?

Steinbach WJ, Benjamin DK Jr, Sleasman JW.

J Pediatr. 2018 Nov;202:4-7.e1. doi: 10.1016/j.jpeds.2018.08.035. No abstract available.

PMID:
30360878
4.

IPEX Syndrome.

Tan QKG, Louie RJ, Sleasman JW.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2004 Oct 19 [updated 2018 Jul 19].

5.

Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.

Mullins TLK, Li SX, Bethel J, Goodenow MM, Hudey S, Sleasman JW; Adolescent Medicine Trials Network for HIV AIDS Interventions.

J Clin Virol. 2018 May;102:7-11. doi: 10.1016/j.jcv.2018.02.001. Epub 2018 Feb 7.

6.

Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.

Williams JC, Zhang X, Karki M, Chi YY, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW.

J Leukoc Biol. 2018 Apr;103(4):671-680. doi: 10.1002/JLB.3A0717-294RR. Epub 2018 Jan 29.

7.

Association Between Breast Milk Bacterial Communities and Establishment and Development of the Infant Gut Microbiome.

Pannaraj PS, Li F, Cerini C, Bender JM, Yang S, Rollie A, Adisetiyo H, Zabih S, Lincez PJ, Bittinger K, Bailey A, Bushman FD, Sleasman JW, Aldrovandi GM.

JAMA Pediatr. 2017 Jul 1;171(7):647-654. doi: 10.1001/jamapediatrics.2017.0378.

8.

Novel pathogenic variants in FOXP3 in fetuses with echogenic bowel and skin desquamation identified by ultrasound.

Louie RJ, Tan QK, Gilner JB, Rogers RC, Younge N, Wechsler SB, McDonald MT, Gordon B, Saski CA, Jones JR, Chapman SJ, Stevenson RE, Sleasman JW, Friez MJ.

Am J Med Genet A. 2017 May;173(5):1219-1225. doi: 10.1002/ajmg.a.38144. Epub 2017 Mar 20.

9.

Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.

Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):241-245. doi: 10.1097/QAI.0000000000001355.

10.

HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication.

Appelberg KS, Wallet MA, Taylor JP, Cash MN, Sleasman JW, Goodenow MM.

AIDS Res Hum Retroviruses. 2017 Jul;33(7):690-702. doi: 10.1089/AID.2016.0273. Epub 2017 Apr 12.

11.

The Regulatory B Cell Compartment Expands Transiently During Childhood and Is Contracted in Children With Autoimmunity.

Kalampokis I, Venturi GM, Poe JC, Dvergsten JA, Sleasman JW, Tedder TF.

Arthritis Rheumatol. 2017 Jan;69(1):225-238. doi: 10.1002/art.39820. Erratum in: Arthritis Rheumatol. 2017 Oct;69(10 ):2080.

12.

Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.

Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, Patton ED, Ren W, Thornton SE, Major-Wilson HO, Puga AM, Sleasman JW, Rudy BJ, Wilson CM, Garvie PA; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

J Neurovirol. 2016 Apr;22(2):218-30. doi: 10.1007/s13365-015-0389-0. Epub 2015 Oct 13.

13.

Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects.

Wallet MA, Buford TW, Joseph AM, Sankuratri M, Leeuwenburgh C, Pahor M, Manini T, Sleasman JW, Goodenow MM.

BMC Immunol. 2015 Jul 24;16:43. doi: 10.1186/s12865-015-0106-z.

14.

Δ(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.

Williams JC, Klein TW, Goldberger BA, Sleasman JW, Mackman N, Goodenow MM.

J Inflamm (Lond). 2015 Jun 12;12:39. doi: 10.1186/s12950-015-0084-1. eCollection 2015.

15.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW; Adolescent Trials Network for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549.

16.

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Niebur HB, Duff CM, Shear GF, Nguyen D, Alberdi TK, Dorsey MJ, Sleasman JW.

Clin Exp Immunol. 2015 Sep;181(3):441-50. doi: 10.1111/cei.12623. Epub 2015 Jul 7.

17.

Recalcitrant rhinosinusitis, innate immunity, and mannose-binding lectin.

Justice JM, Sleasman JW, Lanza DC.

Ann Otol Rhinol Laryngol. 2015 Feb;124(2):102-6. doi: 10.1177/0003489414543680. Epub 2014 Jul 25.

PMID:
25063683
18.

Hypereosinophilic syndrome and hemimelia in a patient with chromosome 6p22.3 deletion.

Ladinsky HT, Elizalde A, Schickler R, Dees PB, Crenshaw ML, Sleasman JW.

Pediatr Allergy Immunol. 2014 Aug;25(5):500-3. doi: 10.1111/pai.12213. Epub 2014 Mar 16. No abstract available.

19.

Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.

Williams JC, Appelberg S, Goldberger BA, Klein TW, Sleasman JW, Goodenow MM.

J Neuroimmune Pharmacol. 2014 Jun;9(3):369-79. doi: 10.1007/s11481-014-9527-3. Epub 2014 Feb 23.

20.

Concordance between self-reported substance use and toxicology among HIV-infected and uninfected at risk youth.

Nichols SL, Lowe A, Zhang X, Garvie PA, Thornton S, Goldberger BA, Hou W, Goodenow MM, Sleasman JW.

Drug Alcohol Depend. 2014 Jan 1;134:376-382. doi: 10.1016/j.drugalcdep.2013.11.010. Epub 2013 Nov 19.

21.

IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus.

Yin L, Hou W, Liu L, Cai Y, Wallet MA, Gardner BP, Chang K, Lowe AC, Rodriguez CA, Sriaroon P, Farmerie WG, Sleasman JW, Goodenow MM.

Front Immunol. 2013 Nov 15;4:373. doi: 10.3389/fimmu.2013.00373. eCollection 2013.

22.

Psychrobacter immobilis septicemia in a boy with X-linked chronic granulomatous disease and fulminant hepatic failure.

Sriaroon P, Elizalde A, Perez EE, Leiding JW, Aldrovandi GM, Sleasman JW.

J Clin Immunol. 2014 Jan;34(1):39-41. doi: 10.1007/s10875-013-9961-7. Epub 2013 Nov 12.

PMID:
24217814
23.

Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Sanou MP, Roff SR, Mennella A, Sleasman JW, Rathore MH, Yamamoto JK, Levy JA.

J Virol. 2013 Sep;87(18):10004-15. doi: 10.1128/JVI.00359-13. Epub 2013 Jul 3.

24.

Bioavailability of IgG administered by the subcutaneous route.

Berger M, Jolles S, Orange JS, Sleasman JW.

J Clin Immunol. 2013 Jul;33(5):984-90. doi: 10.1007/s10875-013-9876-3. Epub 2013 Mar 1.

25.

High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems.

Yin L, Liu L, Sun Y, Hou W, Lowe AC, Gardner BP, Salemi M, Williams WB, Farmerie WG, Sleasman JW, Goodenow MM.

Retrovirology. 2012 Dec 17;9:108. doi: 10.1186/1742-4690-9-108.

26.

Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.

Syed SS, Balluz RS, Kabagambe EK, Meyer WA 3rd, Lukas S, Wilson CM, Kapogiannis BG, Nachman SA, Sleasman JW.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):493-500. doi: 10.1089/AID.2012.0086. Epub 2012 Dec 3.

27.

The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

Wallet MA, Reist CM, Williams JC, Appelberg S, Guiulfo GL, Gardner B, Sleasman JW, Goodenow MM.

J Leukoc Biol. 2012 Oct;92(4):795-805. doi: 10.1189/jlb.0911447. Epub 2012 Jul 11.

28.

Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.

Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG; ATN 061 Team and the Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AIDS Patient Care STDS. 2012 Apr;26(4):193-6. No abstract available.

29.

Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.

Jolles S, Sleasman JW.

Adv Ther. 2011 Jul;28(7):521-33. doi: 10.1007/s12325-011-0036-y. Epub 2011 Jun 14. Review.

PMID:
21681653
30.

Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Haraguchi S, Ho SK, Morrow M, Goodenow MM, Sleasman JW.

J Leukoc Biol. 2011 Oct;90(4):653-60. doi: 10.1189/jlb.0111-009. Epub 2011 Apr 19.

31.

Genome-wide association identifies diverse causes of common variable immunodeficiency.

Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, Kim CE, Hou C, Wang F, Chiavacci R, Kugathasan S, Sleasman JW, Baldassano R, Perez EE, Chapel H, Cunningham-Rundles C, Hakonarson H.

J Allergy Clin Immunol. 2011 Jun;127(6):1360-7.e6. doi: 10.1016/j.jaci.2011.02.039. Epub 2011 Apr 17.

32.

Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.

Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM.

AIDS. 2010 Jun 1;24(9):1281-90. doi: 10.1097/QAD.0b013e328339e228.

33.

Profound reduction of invariant natural killer T cells in the peripheral blood of a patient with interleukin-1 receptor-associated kinase 4 deficiency.

Haraguchi S, Day NK, Tangsinmankong N, Sleasman JW.

Immunol Lett. 2010 Aug 16;132(1-2):86-9. doi: 10.1016/j.imlet.2010.04.011. Epub 2010 May 2.

PMID:
20441778
34.

IFNgamma primes macrophages for inflammatory activation by high molecular weight hyaluronan.

Wallet MA, Wallet SM, Guiulfo G, Sleasman JW, Goodenow MM.

Cell Immunol. 2010;262(2):84-8. doi: 10.1016/j.cellimm.2010.02.013. Epub 2010 Feb 24.

35.

Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.

Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR.

J Clin Immunol. 2010 May;30(3):442-8. doi: 10.1007/s10875-010-9373-x. Epub 2010 Mar 10.

PMID:
20217199
36.

Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Ho SK, Perez EE, Rose SL, Coman RM, Lowe AC, Hou W, Ma C, Lawrence RM, Dunn BM, Sleasman JW, Goodenow MM.

AIDS. 2009 Aug 24;23(13):1631-40. doi: 10.1097/QAD.0b013e32832e0599.

37.

Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents.

Yin L, Kou ZC, Rodriguez C, Hou W, Goodenow MM, Sleasman JW.

Clin Vaccine Immunol. 2009 Sep;16(9):1293-301. doi: 10.1128/CVI.00074-09. Epub 2009 Jul 15.

38.

Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.

Wasserman RL, Church JA, Peter HH, Sleasman JW, Melamed I, Stein MR, Bichler J; IgPro10 in PID Study group.

Eur J Pharm Sci. 2009 Jun 28;37(3-4):272-8. doi: 10.1016/j.ejps.2009.02.014. Epub 2009 Mar 6.

PMID:
19491015
39.

FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

Dorsey MJ, Petrovic A, Morrow MR, Dishaw LJ, Sleasman JW.

Immunol Res. 2009;44(1-3):179-84. doi: 10.1007/s12026-009-8112-y.

PMID:
19471859
40.

Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.

Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV.

Clin Pharmacol Ther. 2009 Apr;85(4):394-401. doi: 10.1038/clpt.2008.236. Epub 2008 Dec 31.

41.

HIV-1 activates macrophages independent of Toll-like receptors.

Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM.

PLoS One. 2008;3(12):e3664. doi: 10.1371/journal.pone.0003664. Epub 2008 Dec 2.

42.

Effects of in vitro brevetoxin exposure on apoptosis and cellular metabolism in a leukemic T cell line (Jurkat).

Walsh CJ, Leggett SR, Strohbehn K, Pierce RH, Sleasman JW.

Mar Drugs. 2008 Jun 10;6(2):291-307. doi: 10.3390/md20080014.

43.

Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, Dunn BM, Sleasman JW, Goodenow MM.

Virology. 2008 Sep 1;378(2):272-81. doi: 10.1016/j.virol.2008.05.029. Epub 2008 Jul 2.

44.

Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.

Yin L, Rodriguez CA, Hou W, Potter O, Caplan MJ, Goodenow MM, Sleasman JW.

J Allergy Clin Immunol. 2008 Jul;122(1):166-72, 172.e1-2. doi: 10.1016/j.jaci.2008.04.029. Epub 2008 Jun 9.

45.
46.

Complete DiGeorge syndrome associated with CHD7 mutation.

Sanka M, Tangsinmankong N, Loscalzo M, Sleasman JW, Dorsey MJ.

J Allergy Clin Immunol. 2007 Oct;120(4):952-4. No abstract available.

PMID:
17931565
47.

Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.

Salemi M, Burkhardt BR, Gray RR, Ghaffari G, Sleasman JW, Goodenow MM.

PLoS One. 2007 Sep 26;2(9):e950.

49.

Thymic output markers indicate immune dysfunction in DiGeorge syndrome.

Lavi RF, Kamchaisatian W, Sleasman JW, Martin DP, Haraguchi S, Day NK, Tangsinmankong N.

J Allergy Clin Immunol. 2006 Nov;118(5):1184-6. Epub 2006 Sep 25. No abstract available.

PMID:
17088147
50.

LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.

Haraguchi S, Day NK, Kamchaisatian W, Beigier-Pompadre M, Stenger S, Tangsinmankong N, Sleasman JW, Pizzo SV, Cianciolo GJ.

AIDS Res Ther. 2006 Mar 31;3:8.

Supplemental Content

Loading ...
Support Center